Orexigen Therapeutics director Eckard Weber resigns
Mr. Weber is a cofounder of Orexigen and has served as a member of the board of directors since company's inception in September 2002. From November 2008 until March 2009, he served as company's interim President and Chief Executive Officer.
Dr. Weber has served as a partner with Domain Associates since 2001. He has over 20 years of drug discovery and development experience. He also served as interim Chief Executive Officer and Chairman of the Board of Sonexa Therapeutics from 2007 until June 2014.
He also serves as chairman of the board at Ocera Therapeutics and Tragara Pharmaceuticals, and is a member of the board of directors of Adynxx, Domain Elite Holdings and Tobira Therapeutics.
Dr. Weber has been the founding Chief Executive Officer of multiple Domain Associates portfolio companies including Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia and Novacardia.
Dr. Weber also served as chairman or member of the board of directors of a number of companies until their sale including Peninsula Pharmaceuticals (sold to Johnson & Johnson in 2005), Cerexa (sold to Forest Laboratories in 2007) and Calixa Therapeutics (sold to Cubist Therapeutics, Inc. in 2009).
Dr. Weber also served as a member of the board of directors of Conforma Therapeutics (sold to Biogen-IDEC in 2006) and Cabrellis Pharmaceuticals (sold to Pharmion in 2006). Until 1995, he was a tenured Professor of Pharmacology at the University of California, Irvine.
Dr. Weber is the inventor or co-inventor of numerous patents and patent applications, and he has published more than 130 papers in scientific periodicals.
Dr. Weber received his German undergraduate degree from Kolping Kolleg in Germany and an M.D. from the University of Ulm Medical School in Germany. He received his postdoctoral training in neuroscience at Stanford University Medical School. ■
LATEST MOVES FROM California
- Banc of California names Doug Bowers as CEO
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
More inside POST